MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Interventions"

  • 2024 International Congress

    Palliative Care in Advanced Parkinson’s Disease: Descriptive Analysis and Symptom Impact

    C. Armengol-García, J. Hartmann-Nava, D. Martínez-Ramírez (Monterrey, Mexico)

    Objective: These preliminary study aims to describe the primary clinical features of Parkinson's disease patients requiring palliative care, as assessed by the Edmonton Symptom Assessment…
  • 2024 International Congress

    Levodopa-Entacapone-Carbidopa Intestinal Gel Treatment In Parkinson’s Disease: A Single-Center Retrospective Chart Study

    AA. Vanderplas (Leiderdorp, Netherlands)

    Objective: The objectives of this chart study were to evaluate adaptations in medication and flow rates and adverse events in patients with Parkinson’s disease (PD)…
  • 2024 International Congress

    Exercise-induced angiogenesis and midbrain neuroprotection in a mouse model of experimental PD

    T. Rodriguez, R. Smeyne, M. Smeyne (Philadelphia, USA)

    Objective: The goal of this study is to characterize microvascular changes in the SNpc in response to a neuroprotective bout of exercise. Background: Parkinson’s disease…
  • 2024 International Congress

    Assessing Feasibility of Using Phone Video Data in Diagnosing Parkinsonism

    Z. Ahmed, S. Desai, A. Deb, S. Roy, D. Desai (Worcester, USA)

    Objective: This project aims to address potential gaps in rural healthcare by assessing the feasibility of using mobile phone data to identify features of parkinsonism…
  • 2024 International Congress

    Safety and Tolerability of Bemdaneprocel in People With Parkinson’s Disease: Results up to 24 Months From a Phase 1 Study

    H. Sarva, C. Henchcliffe, A. Lozano, A. Fasano, S. Kalia, K. Yu, C. Brennan, W. Stemple, N. Abid, M. Yountz, A. Enayetallah, A. Lampron, V. Tabar (New York, USA)

    Objective: To report the safety and tolerability of bemdaneprocel in participants with Parkinson’s disease (PD) up to 24 months post transplantation. Background: Bemdaneprocel is an…
  • 2024 International Congress

    Hospital Care Learning Collaborative: Sharing strategies to address the Parkinson’s Foundation Inpatient Clinical Care Standards

    A. Brooks, E. Buetow, H. Azmi, B. Walter, K. Amodeo, P. Pronovost (Miami, USA)

    Objective: The Parkinson’s Foundation made another significant step toward its vision to eliminate preventable harm and promote higher reliability in care with the launch of…
  • 2024 International Congress

    Motor and Non-Motor Outcomes of Bemdaneprocel in People With Parkinson’s Disease: Results up to 24 Months From a Phase 1 Study

    C. Henchcliffe, H. Sarva, A. Lozano, A. Fasano, S. Kalia, K. Yu, C. Brennan, W. Stemple, N. Abid, M. Yountz, A. Enayetallah, A. Lampron, V. Tabar (Orange, USA)

    Objective: To describe the effects of bemdaneprocel on motor and non-motor outcomes in participants with Parkinson’s disease (PD) up to 24 months post transplantation (12…
  • 2024 International Congress

    Feasibility of a Web Application to Enable Social Interaction in the PREDICT-PD Cohort

    L. Smith, X. Li, A. Gill, P. Panzarasa, J. Bestwick, A. Schrag, A. Noyce, A. de Simoni (London, United Kingdom)

    Objective: This study aims to:(1) Explore the feasibility of delivering a web application to enable social interaction and analyse digital social characteristics.(2) Gather insights into…
  • 2024 International Congress

    Risk Tolerance of Therapeutic Interventions in People with Parkinson’s Disease

    B. Dukes, A. Colombo, K. Patel, D. Shah-Zamora (Winston Salem, USA)

    Objective: To determine the sociodemographic factors of people with Parkinson’s disease (PD) associated with risk tolerance when considering interventions. Background: Gender and racial disparities in…
  • 2024 International Congress

    Safety of Pimavanserin for Parkinson’s Disease Psychosis: Exploratory Analysis of Sedation and Sleep Data From Clinical Studies

    A. Berrio, L. Chrones, V. Abler, R. Hauser (San Diego, USA)

    Objective: To summarize the sleep and sedation-related safety and tolerability of pimavanserin for the treatment of Parkinson’s disease psychosis (PDP). Background: Pimavanserin, a 5-HT2A receptor…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 23
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley